Results 61 to 70 of about 8,677 (217)
Scientific Reports, 2021 The preoperative accurate diagnosis is difficult in the patients with intraductal papillary mucinous neoplasm (IPMN). The aim of the present study was to elucidate the roles of systemic inflammation responses and nutritional status indexes in IPMN.
Yukiyasu Okamura +8 more
doaj +1 more source
Diagnostics, 2022 Intraductal papillary mucinous neoplasms (IPMNs) have a wide pathologic spectrum and it can be difficult to diagnose malignancy, including pathological grade. The aim of this study was to evaluate contrast-enhanced harmonic endoscopic ultrasonography (CH-
Yasunobu Yamashita +9 more
doaj +1 more source
Surveillance and Intervention in IPMN
, 2020 The increasing use of cross-sectional imaging, increasing life expectancy, and a trend for healthy individuals to undergo “health checkups” with full-body magnetic resonance imaging (MRI) have markedly increased the detection of intraductal papillary mucinous neoplasms (IPMNs). IPMNs are a heterogeneous group of pancreatic cystic neoplasms arising from
Balduzzi, A +8 more
openaire +1 more source
Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan +5 more
wiley +1 more source
Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.This review summarises how spatial transcriptomics technologies reveal tumour microenvironment heterogeneity and support the inference of dynamic remodelling during cancer progression. Abstract Background Spatiotemporal transcriptomics (STT) integrates spatially resolved gene expression with temporal information derived from staged samples, paired ...
Ying Kang +9 more
wiley +1 more source
iMeta, Volume 5, Issue 5, October 2026.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
Schema of the epigenetic alterations during pancreatic IPMN progression.
, 2014 Whereas EZH2 is overexpressed during pancreatic IPMN progression, p27Kip1 is inversely downregulated, which leads to accelerated cell proliferation in the malignant IPMN lesions. CIS, carcinoma in situ.
Daisuke Hashimoto (607413) +12 more
core +1 more source
分枝型IPMN症例を膵癌高危険群として集約した検診体系の可能性 [PDF]
, 2010 著者最終原稿版膵管内乳頭粘液性腫瘍(IPMN)は膵管内に粘液産生上皮が乳頭状に増殖する疾患で、病変の主座によって主膵管型と分枝型に分類される。主膵管型IPMNは癌合併率が高いが、分枝型IPMNは無症状例が多く、結節状隆起などの悪性徴候がなければ慎重な経過観察が行われる。しかし、分枝型IPMNを有する症例では、IPMNとは離れた部位に膵癌の合併を3.3〜9.2%に認めることから、膵癌の高危険群と考えられる。分枝型IPMNを膵癌高危険群と認識し、集約した膵癌検診体系を確立することは ...
丹野, 誠志 +5 more
core +1 more source
Endoscopy International Open, 2016 Background: KRAS and GNAS mutations are common in intraductal papillary mucinous neoplasia of the pancreas (IPMN). The aims of this study were to assess the role of pre-therapeutic cytopathology combined with KRAS and GNAS mutation assays within cystic ...
Barbara Bournet +10 more
doaj +1 more source
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer
MedComm, Volume 7, Issue 10, October 2026.Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta +2 more
wiley +1 more source